- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
SLXP Market Currents
more »
-
May 7 Salix Pharmaceuticals (SLXP): Q1 EPS of $0.67 beats by $0.11. Revenue of $171.1M (+62% Y/Y). (PR)
Comment![Earnings, Healthcare]
SLXP in Focus
more »
SLXP Related Articles
more »
SLXP News
more »
-
at MarketWatch.com (Dec 20, 2011)
-
at MarketWatch.com (Nov 9, 2011)
-
at CNBC.com (Mar 22, 2011)
-
at MarketWatch.com (Feb 24, 2011)
-
at MarketWatch.com (Feb 24, 2011)
SLXP Press Releases and Filings
more »
-
Business Wire (May 18, 2012)
-
Business Wire (May 7, 2012)
-
Business Wire (May 1, 2012)
-
Business Wire (Apr 30, 2012)
-
Business Wire (Apr 25, 2012)
SLXP Latest Transcript
more »
-
Mon, Nov 9, 2009Popular searches: salix, slxp, cipla, acquisition, two, year, moviprep, off-label, pharmaceutical, acqui.
SLXP Cramer
more »
Currently, there are no Cramer articles on SLXP.
SLXP Instablog posts
more »
SLXP vs. ETF Alternatives
Company Description
Salix Pharmaceuticals, Ltd., a Delaware corporation, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. Our strategy is... More
